Agilent (A) Surpasses Earnings And Revenue Estimates In Q4
Zacks Investment Research | Nov 19, 2018 08:58PM ET
Agilent Technologies’ (NYSE:A) fiscal fourth-quarter 2018 earnings of 81 cents per share surpassed the Zacks Consensus Estimate by 8 cents. Earnings also increased 20.9% year over year.
Moreover, the company’s fiscal fourth-quarter 2018 revenues of $1.29 billion increased 8.8% year over year. Revenues were ahead of management’s guided range of $1.24-$1.26 billion and also outpaced the Zacks Consensus Estimate of $1.256 billion.
The year-over-year revenue growth was supported by notable improvement across all its product lines and regions.
Coming to share price performance, the stock has lost 3% on a year-to-date basis compared with the industry ’s decline of 3.1%.
Revenues by Segment
Agilent has three reporting segments — Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG), and Diagnostics and Genomics Group (DGG).
In the reported quarter, LSAG was the largest contributor and accounted for $597 million or 46% of the total revenues, reflecting an increase of 8% from the prior-year quarter. This was driven by strength across all major end markets, platforms and regions.
Revenues from ACG came in at $441 million or 34% of its total revenues, reflecting an increase of 9% year over year. Both services and consumables witnessed growth across all geographical regions.
Revenues from DGG came in at $256 million, accounting for the remaining 20% of the total revenues. The segment was up 9% from the year-ago quarter, led by growth in pharma along with strength in genomics and NASD products.
Operating Results
Gross margin in the quarter was 57.8%, up 170 basis points (bps) year over year. The increase was due to higher revenues and a favorable product mix.
Operating expenses (research &development as well as selling, general & administrative expenses) were $460 million, 11.1% higher than the year-ago quarter.
As a result, adjusted operating margin was 25.2%, up 190 bps year over year.
Balance Sheet
At the end of the fiscal fourth quarter, inventories totaled $638 million, reflecting an increase from $623 million in the prior-year quarter. Agilent’s long-term debt was $1.8 billion at the end of the quarter. Cash and cash equivalents were $2.2 billion compared with $2.1 billion in fiscal third-quarter 2018.
In the reported quarter, the company paid $47 million in dividends. In addition, Agilent approved a new share repurchase program of up to $1.75 billion, which will commence on Nov 21, 2018, replacing the previous program.
Guidance
Agilent provided guidance for fiscal first-quarter and full fiscal 2019.
The company expects revenues between $1.265 billion and $1.280 billion, and earnings per share in the range of 71-73 cents for the fiscal first quarter. The Zacks Consensus Estimate is pegged at $1.28 billion for revenues and 73 cents for earnings per share.
For fiscal 2019, Agilent projects revenues in the range of $5.13-$5.17 billion and earnings per share within $3-$3.05.
The Zacks Consensus Estimate for earnings stands at $2.97 per share and that of revenues is $5.19 billion.
Get The News You Want
Agilent Technologies, Inc. Price, Consensus and EPS Surprise
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.